Reviewer's report

Title: The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

Version: 1 Date: 16 June 2012

Reviewer: Rafael Simo

Reviewer's report:

In this mini-review the authors provide a rationale for the intraocular injection of PPAR agonists, particularly fenofibrate or its derivatives, and to encourage further research in this area. Although the authors have not done any research on this issue I consider that this is a well-written and timely review. Nevertheless, the following points should be addressed:

- In the first paragraph at the end of the sentence “Further, there is evidence from smaller studies of a potential benefit of thiazolidinediones (TZDs) on slowing the progression of DR in type 2 diabetes” appropriate references should be included. The following sentence “Thus far, the beneficial effects of these agonists...” is ambiguous. What type of agonists are the authors referring to? Please check this sentence.

- The authors use a lot of general references to PPARs. I recommend they reduce the number of these types of references and add the recent comprehensive review by Ciudin et al (Current Curr Top Med Chem. 2012;12:585-604).

- The mechanistic actions of fenofibrate at retinal level should be completed by adding a brief comment on the following essential references:


**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

No competing interests in relation to the paper.